Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DX25F6XUS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $8,339
Award facts
- Contract value 100% obligated
- $8,339.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 on September 26, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The award, which carries an ultimate completion date of September 29, 2025, was issued by the Defense Logistics Agency's Medical Supply Chain division without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499,999,999 agreement valid through November 2026 that enables the agency to issue firm fixed-price orders for comprehensive pharmaceutical supplies supporting military healthcare facilities worldwide.
Xtandi is a prescription medication used in oncology treatment, consistent with DMS Pharmaceutical Group's established portfolio of delivering specialized pharmaceutical products to federal healthcare systems. The company has demonstrated consistent success in securing federal contracts for branded and generic prescription drugs, biologics, and medical consumables across the Department of Defense healthcare network. This delivery order represents one of numerous pharmaceutical supply acquisitions issued under the larger SPE2DB vehicle, positioning DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical supply chain for military medical facilities.
Quick answers
Who was awarded contract SPE2DX25F6XUS?
SPE2DX25F6XUS was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on September 26, 2025.
How much is contract SPE2DX25F6XUS worth?
The government has obligated $8,339 on SPE2DX25F6XUS.
Is contract SPE2DX25F6XUS an order under another contract?
Yes. SPE2DX25F6XUS is a delivery order under SPE2DX15D9168, an indefinite delivery contract.
Was contract SPE2DX25F6XUS competed?
The extent of competition for SPE2DX25F6XUS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award